Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5845740 | Pulmonary Pharmacology & Therapeutics | 2014 | 15 Pages |
Abstract
Within the lungs, fibrosis can affect both the parenchyma and the airways. Fibrosis is a hallmark pathological change in the parenchyma in patients with idiopathic pulmonary fibrosis (IPF), whilst in asthma or chronic obstructive pulmonary disease (COPD) fibrosis is a component of the remodelling of the airways. In the past decade, significant advances have been made in understanding the disease behaviour and pathogenesis of parenchymal and airway fibrosis and as a result a variety of novel therapeutic targets for slowing or preventing progression of these fibrotic changes have been identified. This review highlights a number of these targets and discusses the potential for treating parenchymal or airway fibrosis through these mediators/pathways in the future.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
C.E. Boorsma, B.G.J. Dekkers, E.M. van Dijk, K. Kumawat, J. Richardson, J.K. Burgess, A.E. John,